Relay Therapeutics (RLAY) Other Non-Current Liabilities (2021 - 2024)
Relay Therapeutics (RLAY) posted quarterly Other Non-Current Liabilities of $11.4 million for Q1 2024, down 63.75% year-over-year from $31.4 million in Q2 2023, and down 13.87% quarter-over-quarter from $13.2 million in Q4 2023.
Relay Therapeutics (RLAY) Other Non-Current Liabilities (2021 - 2024) Analysis & Trends
Relay Therapeutics (RLAY) has reported Other Non-Current Liabilities for 4 consecutive years, with $11.4 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Other Non-Current Liabilities fell 63.75% year-over-year to $11.4 million; the TTM figure through Mar 2024 stood at $11.4 million (down 63.75% YoY), while the FY2023 annual figure was $13.2 million, down 59.21% from the prior year.
- Other Non-Current Liabilities eased to $11.4 million in Q1 2024 per RLAY's latest filing, from $13.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $50.5 million in Q3 2021 and bottomed at $11.4 million in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $35.8 million across 4 years, with a median of $37.6 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities slipped 5.37% — and 2024, when it slumped 63.75%.
- Relay Therapeutics' Other Non-Current Liabilities stood at $50.3 million in 2021, then plunged by 35.58% to $32.4 million in 2022, then tumbled by 59.21% to $13.2 million in 2023, then retreated by 13.87% to $11.4 million in 2024.
- Business Quant data shows RLAY's Other Non-Current Liabilities at $11.4 million in Q1 2024, $13.2 million in Q4 2023, and $28.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 11.37 Mn |
| Dec 31, 2023 | 13.21 Mn |
| Sep 30, 2023 | 28.02 Mn |
| Jun 30, 2023 | 29.22 Mn |
| Mar 31, 2023 | 31.38 Mn |
| Dec 31, 2022 | 32.38 Mn |
| Sep 30, 2022 | 42.92 Mn |
| Jun 30, 2022 | 45.86 Mn |
| Mar 31, 2022 | 45.66 Mn |
| Dec 31, 2021 | 50.26 Mn |
| Sep 30, 2021 | 50.47 Mn |
| Jun 30, 2021 | 48.47 Mn |